Navigation Links
Peregrine Pharmaceuticals Doses First Patient in Phase II Clinical Trial of Bavituximab in Patients With Advanced Breast Cancer
Date:2/12/2008

TUSTIN, Calif., Feb. 12 /PRNewswire-FirstCall/ -- Peregrine Pharmaceuticals, Inc. (Nasdaq: PPHM), a clinical stage biopharmaceutical company developing targeted therapies for the treatment of cancer and hepatitis C virus infection (HCV), today announced that patient dosing has begun in its clinical trial designed to evaluate the safety and efficacy of bavituximab in combination with chemotherapy in patients with advanced breast cancer. The primary objective of the study is to assess the overall response rate to the combination of bavituximab with docetaxel, a chemotherapy drug commonly used in breast cancer. The multicenter clinical trial is being conducted in the Republic of Georgia.

"We are now seeing good overall momentum in our bavituximab Phase II cancer program, and we are very pleased that our clinical colleagues in Europe have been so efficient in rapidly moving from protocol approval to trial initiation to patient dosing," said Steven W. King, president and CEO of Peregrine. "We are optimistic that all three bavituximab Phase II cancer trials will proceed well in the coming months and we look forward to reporting on our progress later this year."

In the trial's two-stage design, up to 15 patients with advanced breast cancer will be enrolled initially. The study will then be expanded up to a total of 46 patients if promising results are observed. Secondary objectives include measuring time to tumor progression, duration of response, overall patient survival and safety parameters. Patients may continue to receive bavituximab alone after completion of chemotherapy as long as the cancer does not progress and side effects are acceptable.

"Bavituximab represents a novel strategy for the treatment of cancer that has
'/>"/>

SOURCE Peregrine Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Peregrine Pharmaceuticals to Present at the 10th Annual BIO CEO & Investor Conference
2. Peregrine Pharmaceuticals Remains on Track to Advance its Three Lead Clinical Programs in 2008
3. Defense Threat Reduction Agency Halts Contract Negotiations With Peregrine Pharmaceuticals as It Suffers $100 Million Cut in FY 2008 Budget for Its Transformational Medical Technologies Initiative (TMTI) Program
4. Peregrine Pharmaceuticals to Announce Second Quarter FY 2008 Financial Results
5. New Data Presented on Immunocytokine Fusion Protein Further Supports Broad Anti-Cancer Potential Of Peregrines Anti-PS Technology Platform
6. Peregrine Pharmaceuticals to Announce First Quarter FY 2008 Financial Results
7. Study Published in Clinical Cancer Research Confirms Potential Of Peregrines Bavituximab Combined With Radiation In Lung Cancer
8. Access Pharmaceuticals to Present at the 10th Annual BIO CEO & Investor Conference
9. XTL Biopharmaceuticals to Present at the 10th Annual BIO CEO & Investor Conference
10. Koronis Pharmaceuticals Appoints David Drajeske Director of Business Development
11. Onyx Pharmaceuticals to Present at BIO CEO & Investor Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/16/2014)... BELLINGHAM, Washington, USA (PRWEB) September 16, 2014 ... how to create the features that we desire in ... Technology Center at Montana State University. “As we explore ... , Some of those lessons were presented in San ... Nature of Light: Light in Nature ” chaired by ...
(Date:9/16/2014)... Sept. 16, 2014  Biocom, the association representing the ... recognizes the 9 th Annual National Health Information ... IT technologies in improving our health care system. ... one of the world,s most vibrant hubs for health ... health applications to genomic testing to remote patient monitoring," ...
(Date:9/16/2014)... Rice University scientists who created a deicing film for ... as a transparent coating for glass. , The ... colleagues could keep glass surfaces from windshields to skyscrapers ... to radio frequencies (RF). , The technology was ... Applied Materials and Interfaces . , The ...
(Date:9/16/2014)... N.Y. , Sept. 16, 2014  Donald Fresne, President ... appointment of Stephan Vagner , PhD to its Scientific ... University of Toulouse, France , performed research ... , and at Inserm, the French institute of health ... and works both at the Curie Institute, Orsay, ...
Breaking Biology Technology:Nature’s designs inspire research into new light-based technologies 2Nature’s designs inspire research into new light-based technologies 3Nature’s designs inspire research into new light-based technologies 4Nature’s designs inspire research into new light-based technologies 5Biocom Recognizes National Health IT Week 2Nanoribbon film keeps glass ice-free 2New Appointment to the Scientific Advisory Committee at Egenix, Inc. 2
... , , , ... RA (TM), a new online talk show hosted by award-winning journalist and ... , , To view the Multimedia News Release, go ... ) , , New Way RA ...
... , SCOTTSDALE, Ariz., July 29 ... subsidiary of IR BioSciences Holdings, Inc. (OTC Bulletin Board: IRBS), ... is both active on oral administration and provides therapeutic effects ... Preliminary analysis of ongoing bioavailability studies in rats ...
... , , SOUTH SAN FRANCISCO, Calif., ... reported financial results for the second quarter ended June 30, 2009. , ... was $3.5 million, with a net loss of $22.9 million, including non-cash ... from operations was $1.9 million for the second quarter and $10.2 million ...
Cached Biology Technology:Video: New Way RA(TM) Talk Show Premieres Online for People Living With Rheumatoid Arthritis (RA) 2Video: New Way RA(TM) Talk Show Premieres Online for People Living With Rheumatoid Arthritis (RA) 3Video: New Way RA(TM) Talk Show Premieres Online for People Living With Rheumatoid Arthritis (RA) 4ImmuneRegen BioSciences Confirms Homspera's Therapeutic Anti-Influenza Effect on Pandemic H1N1 Influenza Virus After Oral Administration 2ImmuneRegen BioSciences Confirms Homspera's Therapeutic Anti-Influenza Effect on Pandemic H1N1 Influenza Virus After Oral Administration 3Sunesis Reports Financial Results for the Second Quarter 2009 2Sunesis Reports Financial Results for the Second Quarter 2009 3Sunesis Reports Financial Results for the Second Quarter 2009 4Sunesis Reports Financial Results for the Second Quarter 2009 5Sunesis Reports Financial Results for the Second Quarter 2009 6Sunesis Reports Financial Results for the Second Quarter 2009 7Sunesis Reports Financial Results for the Second Quarter 2009 8Sunesis Reports Financial Results for the Second Quarter 2009 9Sunesis Reports Financial Results for the Second Quarter 2009 10Sunesis Reports Financial Results for the Second Quarter 2009 11
(Date:9/16/2014)... has its own bacterial identity. That,s the conclusion of ... who studied the genetic fingerprints of bacteria on 57 ... "This study demonstrates for the first time that host ... strategies possess very different microbial communities on their leaves," ... researcher in the UO,s Institute of Ecology and Evolution ...
(Date:9/16/2014)... The fall marks a new school year, a new ... International Space Station. In September, SpaceX,s Dragon spacecraft is ... supplies and investigations as part of the company,s fourth ... cargo will be the third suite of research investigations ... in Space (CASIS). With the role of managing the ...
(Date:9/16/2014)... years after the Hesperides vessel returned to Spain culminating ... have an increasingly clear picture of how the global ... the input of pollutants from the atmosphere is not ... most remote areas of the planet, and it is ... are presented this week in CSIC Residence for Researchers ...
Breaking Biology News(10 mins):Microbiome research shows each tree species has a unique bacterial identity 2CASIS research set for launch aboard SpaceX mission to space station 2CASIS research set for launch aboard SpaceX mission to space station 3The Malaspina Expedition confirms that pollution reaches even the most remote areas of the ocean 2The Malaspina Expedition confirms that pollution reaches even the most remote areas of the ocean 3
... CORVALLIS, Ore. The soils in large areas of the ... America, have been drying up in the past decade, a ... ever examine "evapotranspiration" on a global basis. Most climate ... water from the land to the atmosphere, would increase with ...
... 9, 2010 Help may be on the way for ... the invasion of stink bugs. Scientists have reported a key ... stinkbugs, which are emerging as a major nuisance to homeowners ... a natural substance in a fungus that infects a common ...
... have reported direct evidence that taking up smoking results in ... results were reported at the 35th Congress of the European ... link between smoking and cancer has been established for decades, ... Institute of Cancer Studies, Birmingham, who presented the results. Smoking ...
Cached Biology News:Land 'evapotranspiration' taking unexpected turn: huge parts of world are drying up 2Land 'evapotranspiration' taking unexpected turn: huge parts of world are drying up 3Progress toward first commercial repellent for East Coast's stinker 2Study reveals cancer-linked epigenetic effects of smoking 2
... identification Service includes 1. Scanning of ... 3. High-sensitive tryptic in-gel digestion and ... for MALDI-MS 5. Acquisition of PMF ... (Bruker ultraflex TOF/TOF) 6. Acquisition of ...
Each Yeast-GFP clone represents an individual S. cerevisiae strain containing an open reading frame with a C-terminal Aequorea Victoria GFP (S65T) fusion tag....
... number is a new product number, ... number. If showing no availability yet, ... number (R4276) or contact customer service ... (expanded surface, easy grip) ...
... stored within neurons in vesicles called ... the synaptic bouton. Synaptosomes may ... from other cellular debris. Abnormalites in ... many pathological condtions. Conditions of ...
Biology Products: